Supplementrary figures.docx (3.99 MB)
Download file

IMT-2021-0145 Supplementary Figures

Download (3.99 MB)
figure
posted on 04.08.2021, 10:47 by Figshare Future Science GroupFigshare Future Science Group, Xinke Zhang, Richard W. DeClue, Lisa Herms, Mo Yang, Vivek Pawar, Elizabeth T. Masters, Mary Ruisi, Kevin Chin, Vamsidhar Velcheti

Supplementary Figure 1. Adjusted treatment outcomes including (A) OS, (B) PFS, (C) TTD, and (D) DOR* in the overall population (≥1% PD-L1 expression; N=484).

Supplementary Figure 2. Adjusted treatment outcomes, including (A) OS, (B) PFS, (C) TTD, and (D) DOR* in the low-to-moderate PD-L1 subgroup (1%-49% PD-L1 expression; N=183).

Supplemental Figure 3. Adjusted treatment outcomes, including (A) OS, (B) PFS, (C) TTD, and (D) DOR* in the high PD-L1 subgroup (≥50% PD-L1 expression; N=301).

Real-world treatment patterns and outcomes in PD-L1–positive non-small cell lung cancer

Background

We report real-world treatment patterns and outcomes in patients with PD-L1+ NSCLC.

Methods

This retrospective, observational study using the ConcertAI Oncology Dataset, included patients with PD-L1+ (≥1% expression) metastatic NSCLC who began first-line (1L) treatment between 2016-2019. Treatment outcomes were assessed by treatment class (immune checkpoint inhibitor [ICI] monotherapy, ICI combinations, or chemotherapy).

Results

In total, 128 (25.5%), 237 (47.3%) and 136 patients (27.1%) received 1L chemotherapy, 1L ICI monotherapy, and 1L ICI combinations, respectively. ICI combinations and monotherapy had improved clinical outcomes vs chemotherapy. Adjusted analyses showed no significant difference in outcome between ICI monotherapy and ICI combinations.

Conclusion

ICI-based treatments are being increasingly adopted into clinical practice and were associated with better outcomes vs chemotherapy.

Funding

Merck KGaA, Darmstadt, Germany

Pfizer

History